Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Jan Westerink"'
Autor:
Frank L.J. Visseren, Wendela L de Ranitz, Jan Westerink, Harold W. de Valk, Marieke de Vries, Marga A G Helmink
Publikováno v:
European Journal of Endocrinology. 185:831-840
Objective To identify determinants associated with insulin resistance and to assess the association between insulin resistance and cardiovascular events, vascular interventions and mortality in people with type 1 diabetes at high risk of cardiovascul
Autor:
Helena Bleken, Østergaard, Imre, Demirhan, Jan, Westerink, Marianne C, Verhaar, Folkert W, Asselbergs, Gert J, de Borst, L Jaap, Kappelle, Frank L J, Visseren, Joep, van der Leeuw
Publikováno v:
European Journal of Clinical Investigation. 52
Patients with cardiovascular disease (CVD) are at higher risk of kidney function decline. The current study aimed to examine the association of lifestyle changes with kidney function decline in patients with manifest CVD.A total of 2260 patients from
Autor:
Maria C Castelijns, Marga A G Helmink, Steven H J Hageman, Folkert W Asselbergs, Gert J de Borst, Michiel L Bots, Maarten J Cramer, Jannick A N Dorresteijn, Marielle H Emmelot-Vonk, Mirjam I Geerlings, Pim A de Jong, Niels P van der Kaaij, L Jaap Kappelle, A Titia Lely, Manon G van der Meer, Barend M Mol, Hendrik M Nathoe, N Charlotte Onland-Moret, Rutger B van Petersen, Ynte M Ruigrok, Maarten van Smeden, Martin Teraa, Angela Vandersteen, Marianne C Verhaar, Jan Westerink, Frank L J Visseren
Publikováno v:
BMJ Open. 13:e066952
PurposeThe Utrecht Cardiovascular Cohort–Second Manifestations of Arterial Disease (UCC-SMART) Study is an ongoing prospective single-centre cohort study with the aim to assess important determinants and the prognosis of cardiovascular disease prog
Autor:
Femke V. M. Mulder, Evelien F. H. I. Peeters, Jan Westerink, Fried J. T. Zwartkruis, Wendela L. de Ranitz-Greven
Publikováno v:
Orphanet journal of rare diseases. 17(1)
Background MTOR inhibition is an effective treatment for many manifestations of tuberous sclerosis complex. Because mTOR inhibition is a disease modifying therapy, lifelong use will most likely be necessary. This study addresses the long-term effects
Autor:
Marieke de Vries, Jan Westerink, Fatima El-Morabit, H.A.H. (Karin) Kaasjager, Harold W. de Valk
Publikováno v:
Diabetes research and clinical practice. 186
Assess prevalence of hepatic steatosis (HS) and of fibrosis in an unselected population of patients with type 1 diabetes. Describe their clinical profile and explore the association between insulin resistance and NAFLD as secondary objectives.We pros
Autor:
L. J. Kappelle, Gert J. de Borst, Leonie M. M. Fassaert, Raechel J. Toorop, L. Jaap Kappelle, Bart-Jeroen Petri, Wilton A. van Klei, Eline S. van Hattum, Jan Westerink
Publikováno v:
Annals of vascular surgery. 77
Background Hemodynamic disturbances cause half of the perioperative strokes following carotid endarterectomy (CEA). Guidelines strongly recommend strict pre- and postoperative blood pressure (BP) monitoring in CEA patients, but do not provide firm pr
Publikováno v:
International Journal of Laboratory Hematology
Autor:
Yolanda van der Graaf, Frank L.J. Visseren, Jan Westerink, Peter J. Blankestijn, Michiel L. Bots, Monique E. A. M. van Kleef, Wilko Spiering
Publikováno v:
BMC Endocrine Disorders, Vol 20, Iss 1, Pp 1-8 (2020)
BMC Endocrine Disorders
BMC Endocrine Disorders
Background Satisfactory tools to preclude low-risk patients from intensive diagnostic testing for primary aldosteronism (PA) are lacking. Therefore, we aimed to develop a decision tool to determine which patients with difficult-to-control hypertensio
Autor:
Gert J. de Borst, Yolanda van der Graaf, Maarten J. Cramer, Jan Westerink, Tamar I de Vries, Harold W. de Valk, Frank L.J. Visseren, L. Jaap Kappelle
Publikováno v:
Diabetes Research and Clinical Practice, 157. Elsevier Ireland Ltd
Aims Thyroid dysfunction is a risk factor for cardiovascular disease. Whether thyroid function within the normal range is a risk factor for cardiovascular disease remains uncertain. The aim of this study is to evaluate whether plasma thyroid-stimulat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19e5975cfc0ba16e42598d890a443d3f
https://dspace.library.uu.nl/handle/1874/388851
https://dspace.library.uu.nl/handle/1874/388851
Autor:
Jan Westerink, Frank L.J. Visseren, Tamar I. De Vries, Michiel L. Bots, Folkert W. Asselbergs, Yvo M. Smulders
Publikováno v:
BMJ open, 11(3). BMJ Publishing Group
BMJ Open
BMJ Open, Vol 11, Iss 3 (2021)
BMJ Open
BMJ Open, Vol 11, Iss 3 (2021)
ObjectiveThe aim of the current study was to assess the relationship between classic cardiovascular risk factors and risk of not only the first recurrent atherosclerotic cardiovascular event, but also the total number of non-fatal and fatal cardiovas